Nine Diagnostics joined a coalition of Dutch life sciences companies to co-produce a white paper on advancing diagnostic tools and treatments for gynecological cancers, published November 28, 2024. The collaboration was organized by the Netherlands Innovation Network in Boston, an office of the Dutch Ministry of Economic Affairs, and brought together CC Diagnostics, Predica Diagnostics BV, ViciniVax B.V., and SHE Health Clinics alongside Nine Diagnostics as the U.S. molecular diagnostics partner.
Nine Diagnostics contributed its AI-enabled multiomics nanosensor platform as the proteomics and metabolomics component of the consortium’s diagnostic strategy. The platform generates molecular fingerprints from a single blood draw, simultaneously capturing proteomic, metabolomic, and lipidomic signals across thousands of molecular features without requiring prior identification of which biomarkers to target. The white paper presents a roadmap for U.S.-Dutch collaboration spanning molecular diagnostics, targeted RNA sequencing, therapeutic vaccine development, and women’s health clinical networks, with a focus on cervical and ovarian cancer detection and treatment.
Gynecological cancers, including cervical and ovarian cancer, represent a persistent area of unmet diagnostic need. Ovarian cancer is typically diagnosed at late stage due to the absence of reliable early detection tools, when five-year survival rates are significantly lower than for early-stage disease. Cervical cancer, while preventable through vaccination and screening, continues to carry significant disease burden globally, with access to diagnosis and treatment remaining unequal across populations. Both diseases stand to benefit from molecular diagnostic approaches that do not depend on prior knowledge of disease-specific biomarkers.
The platform’s diagnostic approach builds on published peer-reviewed evidence. Kim et al. (2022) in Nature Biomedical Engineering demonstrated 87% sensitivity and 98% specificity for high-grade serous ovarian cancer detection across 269 patient samples, validating the multiomics fingerprinting approach in a clinical cohort without requiring predetermined biomarkers.
The white paper is available through the Netherlands Innovation Network. This collaboration forms part of the scientific and commercial foundation of Nine Diagnostics, co-founded in 2024 by Daniel A. Heller, PhD (CSO, Head of the Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center), Mijin Kim, PhD, and Freddy T. Nguyen, MD, PhD.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (CEO), Daniel A. Heller, PhD (CSO), and Mijin Kim, PhD (Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.